pGL2-Mcl-1 Citations (7)
Originally described in: Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, Flaherty KT, Smith CD, El-Deiry WS Cancer Cell. 2007 Jul . 12(1):66-80. PubMed Journal
Articles Citing pGL2-Mcl-1
| Articles |
|---|
| A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. Ling X, Cao S, Cheng Q, Keefe JT, Rustum YM, Li F. PLoS One. 2012;7(9):e45571. doi: 10.1371/journal.pone.0045571. Epub 2012 Sep 19. PubMed |
| Regulation of Mcl-1 by constitutive activation of NF-kappaB contributes to cell viability in human esophageal squamous cell carcinoma cells. Liu H, Yang J, Yuan Y, Xia Z, Chen M, Xie L, Ma X, Wang J, Ouyang S, Wu Q, Yu F, Zhou X, Yang Y, Cao Y, Hu J, Yin B. BMC Cancer. 2014 Feb 17;14:98. doi: 10.1186/1471-2407-14-98. PubMed |
| CCN3 overexpression inhibits growth of callosal projections via upregulation of RAB25. Park M, Baek IJ, Kim H, Woo DK, Park YJ, Shim S. Biochem Biophys Res Commun. 2015 Jun 5;461(3):456-62. doi: 10.1016/j.bbrc.2015.04.016. Epub 2015 Apr 12. PubMed |
| PU.1 supports TRAIL-induced cell death by inhibiting NF-kappaB-mediated cell survival and inducing DR5 expression. Haimovici A, Humbert M, Federzoni EA, Shan-Krauer D, Brunner T, Frese S, Kaufmann T, Torbett BE, Tschan MP. Cell Death Differ. 2017 May;24(5):866-877. doi: 10.1038/cdd.2017.40. Epub 2017 Mar 31. PubMed |
| Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression. Xu J, Huang F, Yao Z, Jia C, Xiong Z, Liang H, Lin N, Deng M. Cell Commun Signal. 2019 Jul 26;17(1):85. doi: 10.1186/s12964-019-0398-3. PubMed |
| Chromosome alignment-maintaining phosphoprotein CHAMP1 plays a role in cell survival through regulating Mcl-1 expression. Hino M, Iemura K, Ikeda M, Itoh G, Tanaka K. Cancer Sci. 2021 Sep;112(9):3711-3721. doi: 10.1111/cas.15018. Epub 2021 Jul 16. PubMed |
| ROS-mediated SRMS activation confers platinum resistance in ovarian cancer. Jiang Y, Song L, Lin Y, Nowialis P, Gao Q, Li T, Li B, Mao X, Song Q, Xing C, Zheng G, Huang S, Jin L. Oncogene. 2023 May;42(20):1672-1684. doi: 10.1038/s41388-023-02679-6. Epub 2023 Apr 5. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.